LBA2 Rates of pathologic complete response after VV1 and cemiplimab (alone and in treatment sequence-strategy) in the neoadjuvant setting: Results from the I-SPY 2.2 trial

Résumé fourni par la source

I-SPY 2.2 is a phase 2 platform multiple assignment randomized trial that evaluates novel agents for early breast cancer in 3 neoadjuvant sequential blocks (A/B/C) based on response predictive subtype (RPS) to achieve a pCR. RPS incorporates immune (Im), DNA repair deficiency (DRD), hormone receptor (HR), and HER2 status to classify tumors into 6 subtypes. We report results for intratumoral VV1, an oncolytic vesicular stomatitis virus (VSV), and cemiplimab (Cemi), an anti-PD1 antibody.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.